Role of the receptor for advanced glycation end products in hepatic fibrosis

Table 2 Cell-specific expression of RAGE as determined by immunohistochemistry

	RAGE	CD3	CD68	α-SMA
Normal liver
P	2.8 ± 0.71	3.3 ± 0.7	0.3 ± 0.5	0.8 ± 0.72
L	1.0 ± 0.7	1.5 ± 0.6	0.7 ± 0.6	0.2 ± 0.4
BDL
P	11.1 ± 1.53	13.8 ± 1.2	15.2 ± 1.7	8.1 ± 1.24
L	8.1 ± 1.7	13.2 ± 1.9	13.8 ± 1.6	4.8 ± 1.0
TAA
P	7.3 ± 1.9	8.4 ± 1.1	8.5 ± 1.1	6.8 ± 1.25
L	5.7 ± 1.0	6.6 ± 1.1	6.0 ± 1.1	1.9 ± 0.7

Quantitative analysis of the immunohistochemical co-expression of RAGE with CD3, CD68 and α-SMA in normal controls and livers with cirrhosis due to BDL or TAA-intoxication using double staining immunohistochemistry and image analysis. Mean of cells [%] (± SD) per 10 high power fields. Quantitative assessment as described in material and methods.

¹Mainly endothelial cells in the portal areas;

²Vascular smooth muscle cells, subset of activated HSC;

³Focally highly expressed by proliferating bile duct epithelia;

⁴Mainly around proliferating bile ducts;

⁵Mainly at the portal interface and septa. P: Portal; L: Lobular.